22Reporting requirements

22 Reporting requirements

(1) At the end of each treatment period for an eligible patient, the eligible medical practitioner must give to the Chief Executive Medicare for verification the following: (a) the completed and signed Patient Acknowledgment Form; (b) for each administration of botulinum toxin pharmaceutical benefit in the treatment period—the completed and signed Patient Usage Form. (2) After the end of a treatment period, an eligible medical practitioner must not request the further supply of a botulinum toxin pharmaceutical benefit for the treatment of the eligible patient under this Special Arrangement unless: (a) the requirements of subsection (1) have been met; and (b) the Chief Executive Medicare has verified that the requirements of this Special Arrangement have been complied with for any botulinum toxin pharmaceutical benefit supplied to the eligible medical practitioner for the treatment of the eligible patient under this Special Arrangement.